研究疾病:
|
胃肠道肿瘤相关性疲乏
|
研究疾病代码:
|
|
Target disease:
|
Gastrointestinal Cancer-Related Fatigue
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
采用随机、单盲、安慰灸对照的研究方法,将符合纳入标准的胃肠道肿瘤相关性疲乏患者随机分配到艾灸组与安慰灸对照组(假艾灸)两个组别,借助简易疲乏量表(BFI-C)、生活质量调查问卷(QLQ-C30)、广泛性焦虑障碍量表(GAD-7)、生物学指标(血常规,包括白细胞、血红蛋白、血小板及淋巴细胞;CD3+、CD4+、CD8+、CD4+/CD8+)为评价指标,评价艾灸治疗胃肠道肿瘤相关性疲乏的临床有效性与安全性,以期为艾灸治疗胃肠道肿瘤相关性疲乏提供科学依据。
|
Objectives of Study:
|
Through a randomized, single-blind, placebo-moxibustion-controlled study method, patients with gastrointestinal cancer-related fatigue who met the inclusion criteria were randomly assigned to two groups, the moxibustion group and the placebo moxibustion control group (sham moxibustion group).The evaluation indicators were Brief Fatigue Index (BFI-C), Quality of Life Questionnaire (QLQ-C30), Generalized Anxiety Disorder Scale (GAD-7), biological indicators (blood test, including white blood cells, hemoglobin, platelets and lymphocytes; CD3+, CD4+ , CD8+, CD4+/CD8+) to evaluate the clinical efficacy and safety of moxibustion in the treatment of gastrointestinal cancr-related fatigue, in order to provide a scientific basis for moxibustion in the treatment of gastrointestinal cancer-related fatigue.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1)符合上述胃癌和结直肠癌的诊断标准,TNM分期为Ⅱ~Ⅲ期;符合上述CRF的诊断标准,疲乏发生在胃癌和结直肠癌确诊之后,且与癌症本身或癌症相关治疗有关;
2)年龄18~70岁;
3)ECOG评分≤2分;
4)BFI-C≥4分;
5)预估生存期≥6个月;
6)患者在入组时的前3个月内或之前从未接受过针灸治疗;
7)无精神及智力异常,能理解各项量表条文并完成评定;
8)同意参加本研究并签署书面知情同意书。
|
Inclusion criteria
|
1) Meet the diagnostic criteria for gastric cancer and colorectal cancer, TNM staging is II to III; meet the diagnostic criteria for cancer-related fatigue(CRF), fatigue occurs after the diagnosis of gastric cancer and colorectal cancer, and is related to the cancer itself or cancer-related treatment;
2) Ages range from 18 to 70 years old;
3) ECOG score ≤ 2 points;
4) BFI-C≥4 points;
5) Estimated survival period ≥ 6 months;
6) The patient has never received acupuncture or moxibustion within the first 3 months of enrollment;
7) No mental or intellectual abnormality, able to understand the provisions of various scales and complete the assessment;
8) Agree to participate in this study and sign the written informed consent.
|
排除标准:
|
1)高度怀疑恶性肿瘤,但找不到原发癌灶者;
2)患有重大躯体疾病,如合并较为严重的心、肝、肾等重大疾病;
3)预期寿命小于6个月,或卧床不起者;
4)妊娠或哺乳期患者;
5)有症状的精神疾病及精神障碍者,因吸毒、嗜酒、滥用精神类药物等导致不能正常进行沟通的患者;
6)艾灸部位有溃疡、脓疮、皮肤感染等;
7)患者近1月内因疲乏曾接受艾灸治疗者。
|
Exclusion criteria:
|
1) Those who are highly suspected of malignant tumor but cannot find the primary tumor;
2) Suffering from major physical diseases, such as serious diseases of the heart, liver, kidney, etc.;
3) Life expectancy is less than 6 months, or bedridden;
4) Pregnant or lactating patients;
5) Symptomatic mental illness and mental disorders, patients who cannot communicate normally due to drug addiction, alcohol addiction, abuse of psychotropic substances, etc.;
6) There are ulcers, abscesses, skin infections, etc. at the moxibustion site;
7) Patients who have received moxibustion therapy due to fatigue in the past 1 month.
|
研究实施时间:
Study execute time:
|
从From
2022-07-01
至To
2022-06-30
|
征募观察对象时间:
Recruiting time:
|
从From
2022-08-30
至To
2025-06-30
|